Philip Petteruti

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index797citations41works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(18), Multiple Myeloma Research and Treatments(16), Angiogenesis and VEGF in Cancer(7), PARP inhibition in cancer therapy(7), Cell Adhesion Molecules Research(6)

Publications41 total

Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
2023Open Access
Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis <i>In Vivo</i>
2023Open Access
Supplementary Figures 1-2, Supplementary Tables 1-3 from Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
2023Open Access
Data from Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
2023Open Access
Data from Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
2023Open Access
Supplementary table from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Huawei Chen(29), Tony Cheung(21), Corinne Reimer(21), Paul D. Lyne(21), Stephen E. Fawell(21), Michael Zinda(21), Jonathan R. Dry(20), Deborah Lawson(18), Austin Dulak(17), Maureen M. Hattersley(16), Greg O’Connor(16), Tammie C. Yeh(16), Keith Mikule(14), Wenxian Wang(13), Michael J. Waring(13), Ian L. Dale(12), Scott Boiko(12), Alfred A. Rabow(12), Edwin Clark(12), Jiaquan Wu(12)